新的中期肝细胞癌肝切除标准可提高长期生存率：一项回顾性、多中心协作研究。
New Hepatic Resection Criteria for Intermediate-Stage Hepatocellular Carcinoma Can Improve Long-Term Survival: A Retrospective, Multicenter Collaborative Study.
机构信息
Department of Surgery, Shiga University of Medical Science, Otsu, Japan.
Department of Surgery, Kansai Medical University, Hirakata, Japan.
出版信息
Asian Pac J Cancer Prev. 2020 Oct 1;21(10):2903-2911. doi: 10.31557/APJCP.2020.21.10.2903.
BACKGROUND
Hepatic resection (HR) is not recommended for intermediate-stage hepatocellular carcinoma (HCC) by the Barcelona Clinic Liver Cancer criteria. We examined the prognostic factors of HR for intermediate-stage HCC and developed new HR criteria for intermediate-stage HCC.
METHODS
A total of 110 patients who underwent HR without any prior treatment for intermediate-stage HCC between January 2007 and December 2012 were enrolled at eight university hospitals. The outcomes and prognostic factors of HR were evaluated to develop new HR criteria.
RESULTS
In terms of tumor size and number, the most significant prognostic factors were within the up-to-seven criteria. Furthermore, serum albumin level ≥35 g/L and serum alpha-fetoprotein (AFP) level.
背景
巴塞罗那临床肝癌标准不推荐对中期肝癌进行肝切除术（HR）。我们研究了 HR 治疗中期 HCC 的预后因素，并为中期 HCC 制定了新的 HR 标准。
方法
共纳入 2007 年 1 月至 2012 年 12 月期间在 8 所大学医院因中期 HCC 而未接受任何治疗的 110 例患者，评估 HR 的结果和预后因素，以制定新的 HR 标准。
结果
就肿瘤大小和数量而言，最重要的预后因素在七项标准内。此外，血清白蛋白水平≥35g/L 和血清甲胎蛋白（AFP）水平。
Zotero 插件